Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
GSK plc (GLAXF)
Brentford, GB
GSK plc, a global healthcare and pharmaceutical leader with roots tracing back to 1715, is headquartered in Brentford, United Kingdom. Operating extensively across the UK, United States, and other international markets, its activities span the entire lifecycle of healthcare products, encompassing research, development, manufacturing, and commercialization. Its broad portfolio includes pharmaceuticals, vaccines, over-the-counter medications, and a range of health-focused consumer products. The company operates through four primary divisions: Pharmaceuticals, Pharmaceutical Research & Development, Vaccines, and Consumer Healthcare. Within its pharmaceutical arm, GSK provides therapeutic solutions for a broad spectrum of conditions. These include ailments in respiratory health, HIV, immuno-inflammation, oncology, viral infections, central nervous system disorders, cardiovascular and urogenital issues, metabolic diseases, bacterial infections, and dermatology. The consumer healthcare division delivers products across wellness, oral health, nutrition, and skin health categories. These are available in numerous formats, including nasal sprays, tablets, syrups, lozenges, gum and transdermal patches, caplets, infant syrup drops, liquid suspensions, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams, non-medicated patches, lip balms, gummies, and soft chews. GSK also maintains collaborative agreements with various organizations such as 23andMe, Lyell Immunopharma, Inc., Novartis, Sanofi SA, Surface Oncology, Progentec Diagnostics, Inc., Alector, Inc., and CureVac AG. Furthermore, strategic partnerships are in place with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The firm, known as GlaxoSmithKline plc until its name change to GSK plc in May 2022, embodies centuries of innovation in healthcare.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.83% | -12.92% | -9.29% | +11.96% | +3.54% | +41.50% | +39.49% | +8.89% | -2.00% | +0.87% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%+4.1% Q1'26: +1.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+124.2% ★ Q1'26: +10.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+24.8% ★ Q1'26: +9.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+24.8% ★ Q1'26: +30.3% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+22.8% ★ Q1'26: +56.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%-0.6% ★ Q1'26: -1.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×1.49× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 14 Rev. Ana. 10 EPS Ana. |
Dec 2027 19 Rev. Ana. 6 EPS Ana. |
Dec 2028 8 Rev. Ana. 7 EPS Ana. |
Dec 2029 10 Rev. Ana. 8 EPS Ana. |
Dec 2030 16 Rev. Ana. 12 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
23.92B
est: 52.08B (-54.1%)
|
27.89B
est: 42.06B (-33.7%)
|
30.19B
est: 54.71B (-44.8%)
|
30.82B
est: 49.42B (-37.6%)
|
33.75B
est: 57.13B (-40.9%)
|
34.10B
est: 63.39B (-46.2%)
|
34.11B
est: 61.91B (-44.9%)
|
29.32B
est: 43.31B (-32.3%)
|
30.33B
est: 48.10B (-36.9%)
|
31.38B
est: 38.94B (-19.4%)
|
32.66B
est: 43.78B (-25.4%)
|
45.94B
44.94B – 46.52B
+4.9% YoY
|
48.21B
46.61B – 51.34B
+5.0% YoY
|
49.55B
48.18B – 51.50B
+2.8% YoY
|
51.37B
49.96B – 53.40B
+3.7% YoY
|
50.20B
48.81B – 52.18B
-2.3% YoY
|
| EBITDA |
12.30B
est: 24.60B (-50.0%)
|
4.54B
est: 19.87B (-77.2%)
|
7.15B
est: 25.84B (-72.4%)
|
7.36B
est: 23.34B (-68.5%)
|
9.47B
est: 26.99B (-64.9%)
|
8.07B
est: 29.95B (-73.1%)
|
6.49B
est: 29.25B (-77.8%)
|
8.60B
est: 20.46B (-58.0%)
|
9.08B
est: 22.72B (-60.0%)
|
6.67B
est: 18.40B (-63.8%)
|
11.88B
est: 20.68B (-42.6%)
|
21.70B
21.23B – 21.98B
+4.9% YoY
|
22.77B
22.02B – 24.25B
+5.0% YoY
|
23.41B
22.76B – 24.33B
+2.8% YoY
|
24.27B
23.60B – 25.22B
+3.7% YoY
|
23.71B
23.06B – 24.65B
-2.3% YoY
|
| EBIT |
11.28B
est: 16.45B (-31.4%)
|
2.68B
est: 13.28B (-79.9%)
|
4.26B
est: 17.28B (-75.4%)
|
5.60B
est: 15.61B (-64.1%)
|
7.13B
est: 18.04B (-60.5%)
|
6.02B
est: 20.02B (-69.9%)
|
4.36B
est: 19.55B (-77.7%)
|
6.45B
est: 13.68B (-52.8%)
|
6.79B
est: 15.19B (-55.3%)
|
4.12B
est: 12.30B (-66.5%)
|
8.10B
est: 13.83B (-41.4%)
|
14.51B
14.19B – 14.69B
+4.9% YoY
|
15.23B
14.72B – 16.21B
+5.0% YoY
|
15.65B
15.22B – 16.26B
+2.8% YoY
|
16.22B
15.78B – 16.86B
+3.7% YoY
|
15.85B
15.42B – 16.48B
-2.3% YoY
|
| Net Income |
8.42B
est: 4.65B (+81.0%)
|
912.00M
est: 5.18B (-82.4%)
|
1.53B
est: 6.20B (-75.3%)
|
3.62B
est: 6.06B (-40.2%)
|
4.65B
est: 6.75B (-31.2%)
|
5.75B
est: 6.57B (-12.4%)
|
4.39B
est: 6.17B (-28.9%)
|
14.96B
est: 6.68B (+123.8%)
|
4.93B
est: 7.95B (-38.1%)
|
2.58B
est: 7.98B (-67.7%)
|
5.72B
est: 9.38B (-39.1%)
|
10.01B
9.65B – 10.52B
+6.7% YoY
|
10.99B
10.59B – 11.55B
+9.8% YoY
|
11.47B
11.06B – 12.06B
+4.4% YoY
|
12.19B
11.75B – 12.82B
+6.3% YoY
|
12.29B
11.85B – 12.92B
+0.8% YoY
|
| SGA |
9.23B
est: 16.08B (-42.6%)
|
9.37B
est: 12.99B (-27.9%)
|
9.67B
est: 16.89B (-42.7%)
|
9.92B
est: 15.26B (-35.0%)
|
11.40B
est: 17.64B (-35.4%)
|
11.46B
est: 19.57B (-41.5%)
|
10.98B
est: 19.12B (-42.6%)
|
8.37B
est: 13.37B (-37.4%)
|
9.39B
est: 14.85B (-36.8%)
|
11.02B
est: 12.03B (-8.4%)
|
9.02B
est: 13.52B (-33.3%)
|
14.18B
13.88B – 14.36B
+4.9% YoY
|
14.89B
14.39B – 15.85B
+5.0% YoY
|
15.30B
14.88B – 15.90B
+2.8% YoY
|
15.86B
15.43B – 16.49B
+3.7% YoY
|
15.50B
15.07B – 16.11B
-2.3% YoY
|
| EPS |
2.18
est: 1.13 (+92.9%)
|
0.24
est: 1.26 (-80.9%)
|
0.39
est: 1.51 (-74.1%)
|
0.92
est: 1.47 (-37.5%)
|
1.17
est: 1.64 (-28.7%)
|
1.44
est: 1.59 (-9.7%)
|
1.37
est: 1.50 (-8.6%)
|
3.71
est: 1.62 (+128.6%)
|
1.20
est: 1.93 (-37.9%)
|
0.63
est: 1.94 (-67.5%)
|
1.41
est: 2.28 (-38.1%)
|
2.43
2.34 – 2.56
+6.7% YoY
|
2.67
2.57 – 2.81
+9.8% YoY
|
2.79
2.69 – 2.93
+4.4% YoY
|
2.96
2.85 – 3.11
+6.3% YoY
|
2.99
2.88 – 3.14
+0.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | GSK plc | 1.01M | 4.90% | 1.01M | — | 1.01M | 1.01M | CO | England and Wales | 2023-02-06 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Fidelity International High Quality ETF FCIQ.TO | 0.33% | 4.25M | 0.51% |
| 2 | Fidelity International High Dividend ETF FCID.TO | 0.33% | 803.9K | 0.50% |
| 3 | Fidelity International Value ETF FCIV.TO | 0.31% | 5.12M | 0.50% |
| 4 | Fidelity All-International Equity ETF FCIN.NE | 0.25% | 1.84M | 0.50% |
| 5 | Fidelity All-in-One Growth ETF FGRO.NE | 0.05% | 1.84M | 0.42% |
| 6 | Fidelity All-in-One Balanced ETF FBAL.NE | 0.04% | 2.49M | 0.41% |
| 7 | Fidelity All-in-One Conservative ETF FCNS.NE | 0.03% | 390.4K | 0.40% |
Insider Activity
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Emma Natasha Walmsley | Executive Officer | 8M | female |
| Julie Brown | Chief Financial Officer & Executive Director | 6M | female |
| Luke V. Miels | Chief Executive Officer & Director | 6M | male |
| Jesse L. Goodman | Scientific & Medical Expert | 83.0K | — |
| Philip C. Thomson | President of Global Affairs | — | male |
| Shobie Ramakrishnan | Chief Digital & Technology Officer | — | female |
| Constantin Fest | Senior Vice President & Head of Investor Relations | — | male |
| Tony Wood | Chief Scientific Officer and Head of R&D | — | male |
| David Simon Redfern | President of Corporate Development | — | male |
| Diana Conrad | Chief People Officer | — | female |
| James Ford | Senior Vice President & Group General Counsel of Legal & Compliance | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GLAXF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
